

PATIENT

Patient: SAMPLE PATIENT
DOB/Sex:
MR/Chart #:
Accession #:

SPECIMEN

Specimen: 2 PB NA HEP, 1 PB EDTA
Collected: 12/15/2011
Received: 12/16/2011
All Specimens: 2 PB NA HEP, 1 PB EDTA

PHYSICIAN

SAMPLE DOCTOR
Copies:
REPORT DATE:12/16/2011

CLINICAL HISTORY:

Hepatosplenomegaly, nonpathologically enlarged lymph hilar, peripancreatic lymph nodes, and leukocytosis with thrombocytopenia.

FINAL DIAGNOSIS:

Peripheral Blood Involvement by Mantle Cell Lymphoma

COMPREHENSIVE ASSESSMENT:

The combined morphologic (see IST-11-xx), flow cytometric (FLW-11-xx) and Cytogenetic FISH (CGX-11-xx) studies are consistent with peripheral blood involvement by mantle cell lymphoma. The presence of overt peripheral blood involvement and association with a complex karyotype, including the del(17p) which is commonly associated with loss of TP53, are considered adverse prognostic indicators (WHO 2008 Classification). The final diagnosis was communicated with the ordering physician on 12/16/11.

MORPHOLOGY:

Leukocytosis with Lymphocytosis.


FLOW CYTOMETRY:

Peripheral Blood: **CD5+ Monoclonal B-Cell population identified.**


FISH:

Abnormal clone with IGH/BCL1 fusion, monosomy 13, and del(17p).

Overt peripheral blood involvement with loss of (17p) are poor prognostic indicators



Lambda Monoclonal B-cells



FMC7+ / CD23- B-cells



ATM (11q22) (R) / p53 (17p13) (G)

Our OncoMetrix hematopathologists direct and manage the SCOPE workup for your patients and provide fully integrated results. They carefully choose which tests are necessary based upon patient history, specimen quality and clinical necessity.

Electronically signed on 12/16/2011 5:19 PM by Doug Kingma, M.D. Hematopathologist